









Markets
/
Stocks
/
nasdaq-opk
/

OPKO Health Inc

OPK

1.510USD

+0.120+8.63%

Close 09/18, 16:00（ET）Quotes delayed by 15 min

1.18BMarket Cap

LossP/E TTM



OPKO Health Inc

1.510

+0.120+8.63%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated：2025-09-17

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Strong Buy. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

39 / 72

Overall Ranking

215 / 4723

Industry

Healthcare Providers & Services

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 6 analysts

Strong Buy

Current Rating

3.900

Target Price

+180.58%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

OPKO Health, Inc. is a multinational biopharmaceutical and diagnostics company. The Company focuses on leveraging its discovery, development, and commercialization expertise and novel and proprietary technologies. Its segments include pharmaceutical and diagnostics. The pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain, Rayaldee product sales and its pharmaceutical research and development. The diagnostics segment primarily consists of point-of-care operations. Its pharmaceutical business features Rayaldee, a United States Food and Drug Administration (FDA) approved treatment for secondary hyperparathyroidism (SHPT) in adults with stage three or four chronic kidney disease (CKD) and vitamin D insufficiency, and Somatrogon (hGH-CTP), a once-weekly human growth hormone injection. Its NGENLA (somatrogon-ghla), is a once-weekly, human growth hormone analog indicated for treatment of pediatric patients aged three years and older.

Fairly Valued

The company’s latest PE is -5.48, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 618.23M shares, decreasing 0.09% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 38.16M shares of this stock.

Financial Health

Currency: USD Updated：2025-09-17

The company's current financial score is 6.54, which is lower than the Healthcare Providers & Services industry's average of 7.42. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 156.81M, representing a year-over-year decrease of 13.93%, while its net profit experienced a year-over-year decrease of 1340.48%.

Score

Industry at a Glance

Previous score

6.54

Change



Financials

8.07

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.14

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

5.13

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

5.35

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.01

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated：2025-09-17

The company’s current valuation score is 1.20, which is lower than the Healthcare Providers & Services industry's average of 2.35. Its current P/E ratio is -5.48, which is -28.72% below the recent high of -3.90 and -15.44% above the recent low of -6.32.

Score

Industry at a Glance

Previous score

1.20

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 39/72

No Data

Earnings Forecast

Currency: USD Updated：2025-09-17

The company’s current earnings forecast score is 9.00, which is higher than the Healthcare Providers & Services industry's average of 7.58. The average price target for OPKO Health Inc is 3.00, with a high of 8.50 and a low of 2.00.

Score

Industry at a Glance

Previous score

9.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 6 analysts

Strong Buy

Current Rating

3.900

Target Price

+180.58%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

Total

Median

Average

Company name

Ratings

Analysts

OPKO Health Inc

OPK

Apple Inc

AAPL

GE Vernova Inc

GEV

Avantor Inc

AVTR

Tapestry Inc

TPR

Verisk Analytics Inc

VRSK

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated：2025-09-17

The company’s current price momentum score is 6.21, which is lower than the Healthcare Providers & Services industry's average of 6.88. Sideways: Currently, the stock price is trading between the resistance level at 1.44 and the support level at 1.34, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.24

Change

-0.03

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(1)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

0.009

Buy

RSI(14)

66.714

Neutral

STOCH(KDJ)(9,3,3)

74.056

Buy

ATR(14)

0.047

Low Volatility

CCI(14)

226.322

Overbought

Williams %R

2.857

Overbought

TRIX(12,20)

0.190

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

1.414

Buy

MA10

1.409

Buy

MA20

1.400

Buy

MA50

1.362

Buy

MA100

1.344

Buy

MA200

1.469

Buy

Institutional Confidence

Currency: USD Updated：2025-09-17

The company’s current institutional recognition score is 7.00, which is lower than the Healthcare Providers & Services industry's average of 8.03. The latest institutional shareholding proportion is 77.88%, representing a quarter-over-quarter decrease of 11.91%. The largest institutional shareholder is The Vanguard, holding a total of 38.16M shares, representing 4.81% of shares outstanding, with 12.64% increase in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Frost Gamma Investments Trust

219.80M

-10.90%

Rubric Capital Management LP

48.71M

Holbrook (Bruce C)

40.38M

The Vanguard Group, Inc.

Star Investors

29.42M

+1.01%

Hsiao (Jane H)

33.13M

Frost Group, L.L.C.

30.13M

BlackRock Institutional Trust Company, N.A.

24.77M

-2.03%

GJN 2021 Trust

19.91M

EGN 2021 Trust

19.91M

Geode Capital Management, L.L.C.

8.43M

+0.52%

Risk Assessment

Currency: USD Updated：2025-09-17

The company’s current risk assessment score is 4.56, which is higher than the Healthcare Providers & Services industry's average of 4.17. The company's beta value is 1.48. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.